Back Injectables maker Maiva Pharma raises Rs 1,000 crore to set up new manufacturing unit

The fund has acquired a controlling stake with the capital infusion, making it Maiva Pharma’s first private equity fundraise. Avendus acted as the exclusive financial advisor to Maiva and its shareholders on this transaction.

The company also aims to deploy the proceeds to enhance its capabilities in sterile dosage forms including pre-filled syringes, bags, oncology and hormonal injectables, it said on Thursday.

Maiva already has a plant in Hosur producing sterile injectables in vials and lyophilized vials, with a portfolio of more than 75 products for Contract Development and Manufacturing Organization (CDMO) services, catering to over 40 customers across the US, Canada, Europe, Australia, and Latin American, it said in a statement.

“This fundraise will be used to add more vial, lyophilization, and suspension capacity and introduce new manufacturing capabilities such as prefilled syringes, cartridges and bags,” said Bhaskar Krishna, managing director and chief executive at Maiva Pharma.

Set up in 1993, Maiva Pharma focuses on contract manufacturing of sterile injectables for regulated markets.

Morgan Stanley Private Equity Asia is a leading private equity investor in the Asia-Pacific region, managing third-party money funds and investing in the region for over two decades, primarily through highly structured minority investments and control buyouts in the mid-market segment.

Private equity firm InvAscent manages assets worth $650 million across four funds, tailored for India’s small and mid-market companies across pharma, healthcare delivery, medical devices, other allied sectors.

“We believe that the injectables CDMO market is poised for strong growth and Maiva is well positioned to emerge as one of the leading independent players supplying regulated markets. Under Bhaskar’s leadership, Maiva has put in place building blocks for future growth with a customer-centric approach, sharp R&D focus and an emphasis on maintaining high quality standards,” said Nirav Mehta, managing director and co-head at Morgan Stanley Private Equity Asia.

Related Posts

  • Pharma
  • May 25, 2024
  • 65 views
NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of asthma inhaler drug combination formoteral 6 mcg and budesonide 400 mcg dry power inhaler (DPI) under…

  • Pharma
  • May 25, 2024
  • 75 views
Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Jaipur: To provide quality education in pharmacy institutes, the central government has prepared to end the duplicate system. Strict action will be taken against fake students and teachers in newly opened…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

A Doctor diagnoses Mood of Voters in Delhi

A Doctor diagnoses Mood of Voters in Delhi

NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Tripura Police Seized Banned Cough Syrup Worth Rs 30 Lakh In Dhalai; One Arrested

Tripura Police Seized Banned Cough Syrup Worth Rs 30 Lakh In Dhalai; One Arrested

Ex-Pharmacy Council Registrar Gave Certificates To Ineligible Candidates?

Ex-Pharmacy Council Registrar Gave Certificates To Ineligible Candidates?

Experts Call For Ethical Standards, Patient Advocacy In Clinical Research

Experts Call For Ethical Standards, Patient Advocacy In Clinical Research